We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+0.66%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$167M
AUM Growth
-$1.27M
Cap. Flow
+$3.86M
Cap. Flow %
2.31%
Top 10 Hldgs %
72.22%
Holding
63
New
9
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$944K
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$591K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$506K
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$428K
5
ELUT icon
Elutia
ELUT
+$346K

Top Sells

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$461K
2
NKTR icon
Nektar Therapeutics
NKTR
+$369K
3
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
+$238K
4
BLUE
bluebird bio
BLUE
+$46K
5
OVV icon
Ovintiv
OVV
+$4.03K

Sector Composition

Rank Sector Weight
1 Healthcare 96.67%
2 Energy 1.69%
3 Consumer Staples 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$53.2M 31.82%
796,106
+1,920
+0.2% +$125K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$18M 10.74%
223,286
+1,953
+0.9% +$155K
BDSX icon
3
Biodesix
BDSX
$209M
$14.6M 8.73%
55,248
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$7.8M 4.67%
80,200
– –
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$7.65M 4.57%
59,684
+1,040
+2% +$122K
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.38B
$4.86M 2.91%
199,400
+22,400
+13% +$506K
BIIB icon
7
Biogen
BIIB
$30.4B
$4.19M 2.51%
12,100
– –
ALBO
8
DELISTED
Albireo Pharma Inc
ALBO
$3.9M 2.34%
111,000
– –
FHTX icon
9
Foghorn Therapeutics
FHTX
$305M
$3.35M 2.01%
314,143
– –
UTHR icon
10
United Therapeutics
UTHR
$22.7B
$3.23M 1.93%
18,000
– –
KPTI icon
11
Karyopharm Therapeutics
KPTI
$216M
$2.37M 1.42%
15,333
– –
BLUE
12
DELISTED
bluebird bio
BLUE
$2.37M 1.42%
5,713
-116
-2% -$46K
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$2.34M 1.4%
18,672
– –
MASI
14
DELISTED
Masimo
MASI
$1.94M 1.16%
8,000
– –
ELTX icon
15
Elicio Therapeutics
ELTX
$81.7M
$1.94M 1.16%
6,062
– –
VNDA icon
16
Vanda Pharmaceuticals
VNDA
$327M
$1.72M 1.03%
80,000
– –
HROW icon
17
Harrow
HROW
$1.74B
$1.67M 1%
180,000
– –
PRTA icon
18
Prothena Corp
PRTA
$453M
$1.55M 0.93%
+30,247
New +$944K
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.5M 0.9%
22,000
– –
CLR
20
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$1.47M 0.88%
38,600
– –
AMRN
21
Amarin Corp
AMRN
$292M
$1.31M 0.79%
15,000
– –
IMGN
22
DELISTED
Immunogen Inc
IMGN
$1.25M 0.75%
190,000
– –
NKTR icon
23
Nektar Therapeutics
NKTR
$2.31B
$1.24M 0.74%
4,800
-1,333
-22% -$369K
ALKS icon
24
Alkermes
ALKS
$8.79B
$1.23M 0.73%
50,000
+15,000
+43% +$334K
CGEM icon
25
Cullinan Oncology
CGEM
$1.09B
$1.16M 0.7%
45,114
-15,000
-25% -$461K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Birchview Capital held 63 positions worth $167M, down 0.75% from $168M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Birchview Capital's Q2 2021 filing shows 9 new, 5 increased, 4 reduced and 1 closed positions. Its largest new stake was Prothena Corp: 30,247 shares worth $1.55M. The largest sale was Cullinan Oncology, an estimated $461K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2021 buy was Prothena Corp: 30,247 shares worth $1.55M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q2 2021, an estimated $506K increase.
  • Birchview Capital's biggest Q2 2021 reduction was Cullinan Oncology, cutting an estimated $461K.
  • Birchview Capital fully exited Yield10 Bioscience, Inc. Common Stock in Q2 2021, selling an estimated $238K.
  • Birchview Capital's ten largest holdings make up 72% of its $167M portfolio in Q2 2021.
  • Birchview Capital opened 9 new positions and closed 1 in Q2 2021.
  • Birchview Capital's portfolio value fell 0.75% quarter-over-quarter to $167M.

Based on Birchview Capital's 13F filing for Q2 2021, filed 10 Aug 2021.